Cargando…

2226. Trough- Versus AUC-Based Vancomycin Monitoring for Treatment of Acute Pulmonary Exacerbations of Adult Cystic Fibrosis Patients

BACKGROUND: Therapeutic drug monitoring (TDM) for IV vancomycin (VAN) in adults with cystic fibrosis (CF) historically has utilized trough concentrations. Recent VAN TDM guidelines recommend area under the curve (AUC)-monitoring to reduce the risk of vancomycin-induced kidney injury. However, limite...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Darrell, Monogue, Marguerite, Sanders, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678331/ http://dx.doi.org/10.1093/ofid/ofad500.1848

Ejemplares similares

1315. Ceftaroline Versus Vancomycin for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis in Adults
por: Esquivel, Marc, et al.
Publicado: (2021)

2558. Association of Vancomycin-Induced Acute Kidney Injury with Trough Versus AUC Monitoring in Patients Receiving Extended Durations of Therapy
por: Pitcock, C Tyler, et al.
Publicado: (2023)

220. Acute kidney injury incidence comparison of vancomycin trough-based vs AUC/MIC monitoring at a tertiary care hospital
por: Ruiz Gaviria, Rafael E, et al.
Publicado: (2022)

Impact of Vancomycin Serum Trough Concentrations and Vancomycin AUC/MIC on Vancomycin Response, In-Hospital Outcomes and Acute Kidney Injury in Pediatric Staphylococcus aureus Pneumonia
por: McNeil, Jonathon, et al.
Publicado: (2017)

1327. Vancomycin Dosing by AUC(24)/MIC in Comparison to Traditional Trough Dosing in Office Infusion Centers (OICs)
por: Luu, Quyen, et al.
Publicado: (2020)

Implementation of a Vancomycin AUC Monitoring Program: Peaks and Pitfalls
por: Kassamali, Zahra, et al.
Publicado: (2017)

The relationship between vancomycin AUC/MIC and trough concentration, age, dose, renal function in Chinese critically ill pediatric patients
por: Chen, Jihui, et al.
Publicado: (2021)

1097. A Comparison of Area-Under Curve (AUC)-Guided vs Trough-Guided Monitoring of Vancomycin and Its Impact on Nephrotoxicity: A Systematic Review and Meta-analysis
por: Lim, Ashley Shiyuan, et al.
Publicado: (2021)

1323. Efficacy and Safety of Telavancin Compared to Vancomycin for Cystic Fibrosis Pulmonary Exacerbation in Adults
por: Shorman, Mahmoud, et al.
Publicado: (2021)

Educational Resource Review: The case for AUC dosing of vancomycin
Publicado: (2020)

1328. Vancomycin exposure and utilization following implementation of an AUC-guided monitoring guideline in children
por: Quraishi, Ruquaya, et al.
Publicado: (2020)

1222. Ceftolozane-Tazobactam Heteroresistance in Cystic Fibrosis Related Pseudomonas aeruginosa Infections
por: Sanders, James, et al.
Publicado: (2021)

2193. Vancomycin AUC:MIC Monitoring: Transitioning Safely from Inpatient to Outpatient Monitoring via OPAT
por: Campion, Maureen, et al.
Publicado: (2023)

Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis
por: DiMango, Emily, et al.
Publicado: (2014)

775. Comparison of Initial Vancomycin Costs and Target Attainment Between Trough- and 24-Hour Area Under the Concentration–Time Curve (AUC24)-Guided Dosing
por: Laurent, David, et al.
Publicado: (2019)

1090. Does calculation method matter for targeting vancomycin AUC?
por: Chang, Jack, et al.
Publicado: (2021)

Therapeutic drug monitoring of vancomycin by AUC(τ)-MIC ratio in patients with chronic kidney disease
por: Khoei, Ahmad, et al.
Publicado: (2019)

Evaluation of traditional initial vancomycin dosing versus utilizing an electronic AUC/MIC dosing program
por: Mcgrady, Kerri A., et al.
Publicado: (2020)

599. Association between Vancomycin AUC and Clinical Failure in Patients with Streptococcal Bacteremia
por: Aycock, Anna C, et al.
Publicado: (2022)

Vancomycin trough level and loading dose
por: Tuon, Felipe Francisco, et al.
Publicado: (2018)

349. The impact of Vancomycin dosing by area under the curve over minimal inhibitory concentration (AUC/MIC) versus Trough levels on cumulative Vancomycin dosage and incidence of Acute Kidney Injury (AKI) in patients admitted to intensive care units (ICU)
por: Sahu, Aniruddha, et al.
Publicado: (2023)

Clinical and Pharmacokinetic Outcomes of Peak–Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial
por: Al-Sulaiti, Fatima Khalifa, et al.
Publicado: (2019)

1570. Association Between Vancomycin Area Under the Curve (AUC) and Nephrotoxicity
por: Poston-Blahnik, Anna, et al.
Publicado: (2019)

487 Evaluating use of doxycycline versus vancomycin for treatment of methicillin-resistant Staphylococcus aureus–associated acute pulmonary exacerbations in people with cystic fibrosis
por: Brickel, K., et al.
Publicado: (2022)

Ceftolozane/tazobactam heteroresistance in cystic fibrosis-related Pseudomonas aeruginosa infections
por: Monogue, Marguerite L, et al.
Publicado: (2023)

Acute hyperglycaemia in cystic fibrosis pulmonary exacerbations
por: Merjaneh, Lina, et al.
Publicado: (2020)

Different Vancomycin Immunoassays Contribute to the Variability in Vancomycin Trough Measurements in Neonates
por: Samardzic, Janko, et al.
Publicado: (2016)

The Whole Price of Vancomycin: Toxicities, Troughs, and Time
por: Jeffres, Meghan N.
Publicado: (2017)

1568. The Pharmacodynamic–Toxicodynamic Relationship of AUC and CMAX in Vancomycin-Induced Kidney Injury
por: Avedissian, Sean N, et al.
Publicado: (2019)

1107. Vancomycin AUC Dosing: Is One Concentration in the Hand Worth Two in the Bush?
por: Spivey, Justin, et al.
Publicado: (2021)

1571. Evaluation of a Single Post First Dose Vancomycin Level to Achieve a Goal Vancomycin AUC
por: Hurley, Evan, et al.
Publicado: (2019)

Accurate stereochemistry for two related 22,26-epiminocholestene derivatives
por: Vega-Baez, José Luis, et al.
Publicado: (2008)

Smartphone-Based pH Sensor for Home Monitoring of Pulmonary Exacerbations in Cystic Fibrosis
por: Sun, Alexander, et al.
Publicado: (2017)

Evaluation of a Novel Glucose Area Under the Curve (AUC) Monitoring System: Comparison with the AUC by Continuous Glucose Monitoring
por: Ugi, Satoshi, et al.
Publicado: (2016)

Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis
por: Sawant, Akhil, et al.
Publicado: (2018)

Evaluation of Copeptin during Pulmonary Exacerbation in Cystic Fibrosis
por: Wojsyk-Banaszak, I., et al.
Publicado: (2019)

Lung ultrasound for the diagnosis of cystic fibrosis pulmonary exacerbation
por: Hassanzad, Maryam, et al.
Publicado: (2021)

Elevated Vancomycin Trough Concentration: Increased Efficacy and/or Toxicity?
por: Elyasi, Sepideh, et al.
Publicado: (2014)

Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis
por: Bouzek, Drake C., et al.
Publicado: (2022)

Vancomycin therapeutic monitoring by measured trough concentration versus Bayesian‐derived area under the curve in critically ill patients with cancer
por: AbuSara, Aseel K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bua37k8agfseldlpba3soisp5l